Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Licenses Technology to Nanosphere for $1.9M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Acceler8 and Nanosphere have reached a non-exclusive licensing agreement for Acceler8's surface coating technology.

The deal, disclosed in a document filed by Nanosphere with the US Securities and Exchange Commission, covers "a coating to be applied to a single discrete physical substrate component article." The coating is "a polymer formulation comprising of an active component comprising polyethylene glycol polymer; a matrix-forming component; and a cross-linking component."

Under the terms of the deal, Nanosphere will pay Accelr8 a license and technology transfer fee of almost $1.9 million payable in four installments. The first installment of $165,000 was due upon execution of the deal. The remaining installments — $350,000, $600,000, and $750,000 — are due on July 9, 2011, 2012, and 2013, respectively.

The deal was reached on July 9, said Nanosphere.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.